Brief: Cocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 As Norovirus Lead
08/08/2023 13:53
Aug 8 (Reuters) - Cocrystal Pharma Inc COCP.O :
* COCRYSTAL PHARMA SELECTS NOVEL ORAL PROTEASE INHIBITOR
CDI-988
AS NOROVIRUS LEAD
Source text for Eikon: ID:nGNXbbhv0k
Further company coverage: COCP.O
Recent news on Cocrystal Pharma
See all newsBrief: Cocrystal Pharma Announces Last Subject Dosed In Phase 1b Human Challenge Study Evaluating CDI-988 For Norovirus Prevention And Treatment
Cocrystal Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Cocrystal Pharma Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway